MX2022013503A - Uso de derivado de glutarimida para superar la resistencia a esteroides y tratar enfermedades relacionadas con la se?alizacion aberrante del interferon gamma. - Google Patents

Uso de derivado de glutarimida para superar la resistencia a esteroides y tratar enfermedades relacionadas con la se?alizacion aberrante del interferon gamma.

Info

Publication number
MX2022013503A
MX2022013503A MX2022013503A MX2022013503A MX2022013503A MX 2022013503 A MX2022013503 A MX 2022013503A MX 2022013503 A MX2022013503 A MX 2022013503A MX 2022013503 A MX2022013503 A MX 2022013503A MX 2022013503 A MX2022013503 A MX 2022013503A
Authority
MX
Mexico
Prior art keywords
steriods
lupus erythematosus
systemic lupus
novel
overcoming resistance
Prior art date
Application number
MX2022013503A
Other languages
English (en)
Inventor
Vladimir Evgenievich Nebolsin
Original Assignee
Chemimmune Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemimmune Therapeutics Llc filed Critical Chemimmune Therapeutics Llc
Publication of MX2022013503A publication Critical patent/MX2022013503A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a la medicina, en particular, a un nuevo fármaco efectivo para el tratamiento de enfermedades relacionadas con la señalización aberrante de interferón gamma, tal como síndrome de Sjögren, dermatomiositis, lupus eritematoso sistémico o esclerosis sistémica; para el tratamiento de pacientes que padecen tos; y para el tratamiento de trastornos en pacientes resistentes a los esteroides, tal como asma, artritis reumatoide, lupus eritematoso sistémico y enfermedades gastrointestinales, al administrar un compuesto 1-(2-(1H-imidazol-4-il)etil) piperidin-2,6-diona (ver Fórmula); la invención proporciona la creación de un nuevo fármaco efectivo para superar la resistencia a los esteroides.
MX2022013503A 2018-11-23 2021-05-21 Uso de derivado de glutarimida para superar la resistencia a esteroides y tratar enfermedades relacionadas con la se?alizacion aberrante del interferon gamma. MX2022013503A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2018141291A RU2712281C1 (ru) 2018-11-23 2018-11-23 Применение производного глутаримида для преодоления резистентности к стероидам и терапии заболеваний, ассоциированных с аберрантным сигналингом интерферона гамма

Publications (1)

Publication Number Publication Date
MX2022013503A true MX2022013503A (es) 2022-11-16

Family

ID=69624712

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021006032A MX2021006032A (es) 2018-11-23 2019-11-22 Uso de derivado de glutarimida para superar la resistencia a esteroides y tratar enfermedades relacionadas con la señalización aberrante del interferón gamma.
MX2022013503A MX2022013503A (es) 2018-11-23 2021-05-21 Uso de derivado de glutarimida para superar la resistencia a esteroides y tratar enfermedades relacionadas con la se?alizacion aberrante del interferon gamma.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2021006032A MX2021006032A (es) 2018-11-23 2019-11-22 Uso de derivado de glutarimida para superar la resistencia a esteroides y tratar enfermedades relacionadas con la señalización aberrante del interferón gamma.

Country Status (18)

Country Link
US (1) US20220362230A1 (es)
EP (2) EP3884945A4 (es)
JP (2) JP2022508167A (es)
KR (2) KR20210095652A (es)
CN (2) CN113164464A (es)
AU (2) AU2019384626A1 (es)
BR (1) BR112021009801A2 (es)
CA (1) CA3120882A1 (es)
CL (2) CL2021001316A1 (es)
EA (1) EA201992646A1 (es)
GE (1) GEP20237467B (es)
IL (2) IL297533A (es)
MD (2) MD4851C1 (es)
MX (2) MX2021006032A (es)
PH (1) PH12021551152A1 (es)
RU (1) RU2712281C1 (es)
WO (1) WO2020106191A1 (es)
ZA (2) ZA202104247B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023177329A1 (ru) * 2022-03-18 2023-09-21 Общество С Ограниченной Ответственностью "Валента-Интеллект" Применение 1-(2-(1н-имидазол-4-ил)этил)пиперидин-2,6-диона для лечения кашля, вызванного вирусными инфекциями
WO2023191666A1 (ru) * 2022-03-29 2023-10-05 Общество С Ограниченной Ответственностью "Валента-Интеллект" Кристаллическая форма 1-(2-(1н-имидазол-4-ил)этил)пиперидин-2,6-диона и ее применение

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE9111874U1 (es) * 1991-09-23 1991-11-21 Haag, Richard, 7181 Satteldorf, De
CZ188394A3 (en) * 1992-02-07 1996-02-14 Albert M Kligman Pharmaceutical preparation for the control of inflammatory dermatose cleaning and the use of corticosteroidal matter in combination with a retoidal matter for preparing such preparations
US7544772B2 (en) * 2001-06-26 2009-06-09 Biomarck Pharmaceuticals, Ltd. Methods for regulating inflammatory mediators and peptides useful therein
US20040220155A1 (en) * 2003-03-28 2004-11-04 Pharmacia Corporation Method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith
RU2404792C1 (ru) * 2009-05-20 2010-11-27 Общество с ограниченной ответственностью Научно-производственное предприятие "БИОНОКС" Средство для преодоления стероидной резистентности
US20140112913A1 (en) * 2011-02-10 2014-04-24 Genqual Corporation Methods of prognosing and administering treatment for inflammatory disorders
MX2020005736A (es) * 2013-04-12 2021-06-14 Obschestvo S Ogranichennoi Otvetstvennostiyu Pharmenterprises Derivados de glutarimida, uso de los mismos, composicion farmaceutica basada en los mismos y metodos para producir derivados de glutarimida.
RU2552929C1 (ru) * 2013-11-14 2015-06-10 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний

Also Published As

Publication number Publication date
GEP20237467B (en) 2023-02-10
CL2021001316A1 (es) 2021-10-29
PH12021551152A1 (en) 2021-10-25
EA201992646A1 (ru) 2020-05-31
CA3120882A1 (en) 2020-05-28
ZA202104247B (en) 2023-03-29
AU2022256212A1 (en) 2022-12-08
WO2020106191A1 (ru) 2020-05-28
MD4844B1 (ro) 2023-02-28
EP4218758A2 (en) 2023-08-02
BR112021009801A2 (pt) 2022-03-03
ZA202210444B (en) 2023-01-25
KR20210095652A (ko) 2021-08-02
JP2022508167A (ja) 2022-01-19
CN114652721A (zh) 2022-06-24
RU2712281C1 (ru) 2020-01-28
EP3884945A1 (en) 2021-09-29
IL297533A (en) 2022-12-01
KR20220162821A (ko) 2022-12-08
MD20210050A2 (ro) 2021-12-31
MD20210032A2 (ro) 2021-09-30
CL2022000683A1 (es) 2022-10-28
MD4851B1 (ro) 2023-04-30
EP3884945A4 (en) 2022-11-23
MX2021006032A (es) 2021-07-06
US20220362230A1 (en) 2022-11-17
EP4218758A3 (en) 2023-08-23
CN113164464A (zh) 2021-07-23
MD4844C1 (ro) 2023-09-30
IL283317A (en) 2021-07-29
MD4851C1 (ro) 2023-11-30
JP2023015333A (ja) 2023-01-31
AU2019384626A1 (en) 2021-07-15

Similar Documents

Publication Publication Date Title
MX2022013503A (es) Uso de derivado de glutarimida para superar la resistencia a esteroides y tratar enfermedades relacionadas con la se?alizacion aberrante del interferon gamma.
MX2023009610A (es) Esteroides neuroactivos, y su metodo de uso.
MX2021005691A (es) Formulaciones de farmacos resistentes al alcohol.
PH12021550310A1 (en) Novel sulfonamideurea compounds
MX2021004431A (es) Procesos novedosos.
MX2021007970A (es) Derivado de 6-oxo-1,6-dihidropiridazina, metodo de preparacion del mismo y uso medico del mismo.
NZ765590A (en) Diaryl substituted 5,5-fused ring compounds as c5ar inhibitors
MX2021012903A (es) Moduladores de la via de respuesta integrada al estres.
MX2020006459A (es) Compuestos de anillos fusionados 6,5 diaril sustituidos como inhibidores de c5ar.
EA202192900A1 (ru) Модуляторы пути интегрированной реакции на стресс
PH12020550503A1 (en) Pyridine carbonyl derivatives and therapeutic uses thereof as trpc6 inhibitors
AU2018277520A1 (en) 6-5 fused rings as C5a inhibitors
GB201907616D0 (en) Novel compounds and pharmaceutical compositons thereof for the treatment of diseases
MX2020001531A (es) Nuevos compuestos hetorociclicos como inhibidores de cdk8/19.
EA202091604A1 (ru) Ингибирование ионного канала a1 с транзиторным рецепторным потенциалом
EA202190586A1 (ru) N-замещенные диоксоциклобутениламино-3-гидроксипиколинамиды, приемлемые в качестве ингибиторов ccr6
MX2021003945A (es) Compuestos de indolinona para uso como inhibidores de map4k1.
MX2021009539A (es) Derivado del profarmaco 6-oxo-1,6-dihidropiridazina, metodo de preparacion del mismo y aplicacion del mismo en medicina.
PH12020500461A1 (en) 1-(4-(isoxazol-5-yl)-1h-pyrazol-1-yl)-2-methylpropan-2-ol derivatives and related compounds as il-17 and ifn-gamma inhibitors for treating autoimmune diseases and chronic inflammation
BR112022007489A2 (pt) Forma amorfa de um receptor c5a de componente do complemento
MX2022009243A (es) Moduladores de la via de respuesta integrada al estres.
MX2023007476A (es) Derivado de tetrahidroquinolina y uso medico del mismo.
MX2023006578A (es) Heteroaril-acetilenos, sus composiciones farmacéuticas y sus aplicaciones terapéuticas.
MX2021001335A (es) Inhibidores de ckd8/19.
RU2014147728A (ru) Производное транс-2-деценовой кислоты и содержащее его лекарственное средство